首页> 中文期刊> 《中国社区医师》 >多种血清肿瘤标志物(CY211、NSE、CEA、CA125、CA199、SCC)对不同病理类型和临床分期肺癌的诊断价值

多种血清肿瘤标志物(CY211、NSE、CEA、CA125、CA199、SCC)对不同病理类型和临床分期肺癌的诊断价值

         

摘要

Objective:To analyze the diagnostic value of multiple serum tumor markers(CY211,NSE,CEA,CA125,CA199,SCC) in different pathological types and clinical stages of lung cancer.Methods:80 patients with lung cancer were selected.The levels of CY211,NSE,CEA,CA125,CA199,SCC in the serum of patients were determined by chemiluminescence method.Results:The highest positive rate of squamous cell carcinoma was SCC,and the positive rate was 52.6% .The highest positive rate of adenocarcinoma was CEA,and the positive rate was 45.2%.In the stages of patients with squamous cell carcinoma,the positive rates of SCC in Ⅱstage、Ⅲstage were significantly higher than that of Ⅰstage(P<0.05).Conclusion:Combined examination can effectively improve the accuracy of diagnosis rate of lung cancer.In the clinical examination,the doctor may choose different serum markers according to the patient's pathological type to carry out a combined examination.%目的:分析多种血清肿瘤标志物(CY211、NSE、CEA、CA125、CA199、SCC)对不同病理类型和临床分期肺癌的诊断价值。方法:收治肺癌患者80例,采取化学发光法测定患者血清中 CY211、NSE、CEA、CA125、CA199、SCC 的水平。结果:鳞癌患者 SCC 阳性率最高,阳性率52.6%;腺癌患者 CEA 阳性率最高,阳性率45.2%。鳞癌患者分期中Ⅱ期、Ⅲ期的 SCC 阳性率明显高于Ⅰ期(P<0.05)。结论:联合检查能有效提高肺癌诊断率的准确性,临床检查中,医生可根据患者的病理类型选择不同的血清标志物进行联合检查。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号